Jun. 12, 2019—Doctors formerly had to extract the malaria parasite’s DNA first, virtually impossible to do in rural, low-resource areas.
Jul. 20, 2018—In new research, Hassane Mchaourab and colleagues have uncovered new insights into drug resistance that could lead to the development of new anti-cancer and antibacterial drugs.
Jun. 11, 2018—Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis.
Apr. 11, 2018—Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.
Oct. 17, 2017—Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.
May. 4, 2017—Last month, Vanderbilt Clinical Laboratories introduced rapid molecular diagnostic testing to more quickly identify microorganisms that may be causing a patient’s bloodstream infection, along with the organism’s susceptibility to drugs.
Feb. 10, 2016—Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.
Feb. 5, 2016—Vanderbilt investigators are exploring the shape changes in a multidrug transporter to understand the mechanisms of antibacterial resistance.
Dec. 10, 2015—Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer.
Nov. 4, 2015—Understanding factors, such as the receptor TLR9, that detect and defend against pathogens may lead to therapeutic approaches that promote an effective immune response to treat infections.
Feb. 10, 2015—New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target.
Oct. 29, 2014—A combination of two types of therapy may be more effective in treating castration-resistant prostate cancer.